GlassScriptPhysician profile
Dilmon N Abdullah
NPI 1467876821
$1,960.95
in general payments reported to CMS, 2019-2025
20 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $578 · 2023: $706 · 2024: $416 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $560.60 | 2021-2024 | Proclaim, Eterna, Octrode |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $385.46 | 2022-2024 | Relistor |
| Protega Pharmaceutials INC | $285.42 | 2022-2023 | Roxybond |
| Scilex Pharmaceuticals INC. | $186.18 | 2022-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $126.61 | 2022-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $125.34 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Averitas Pharma INC. | $39.52 | 2025 | Qutenza |
| Pfizer INC. | $35.47 | 2021 | |
| Lilly USA, LLC | $24.65 | 2021 | |
| Phadia US INC. | $24.48 | 2024 | Immunocap |
| Redhill Biopharma INC. | $23.68 | 2022 | |
| Novo Nordisk INC | $21.05 | 2025 | |
| Arbor Pharmaceuticals, INC. | $17.60 | 2022 | |
| Abbvie INC. | $17.46 | 2022 | |
| Hikma Pharmaceuticals USA | $17.33 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $17.15 | 2023 | Horizant |
| Corcept Therapeutics | $15.28 | 2024 | Korlym |
| Cipher Pharmaceuticals US LLC | $13.84 | 2025 | Spinosad, Natroba |
| Kowa Pharmaceuticals America, INC. | $12.52 | 2022 | |
| Grt US Holding, INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilmon Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.